

The Senate

Standing Committee on
Community Affairs

Breaking the silence: a national
voice for gynaecological cancers

October 2006

© Commonwealth of Australia 2006

ISBN 0 642 71680 3

Senate Community Affairs Committee Secretariat:

Mr Elton Humphery (Secretary)

Ms Christine McDonald (Principal Research Officer)

Ms Kerrie Martain (Principal Research Officer)

Ms Kate Palfreyman (Principal Research Officer)

Ms Leonie Peake (Research Officer)

Ms Ingrid Zappe (Executive Assistant)

The Senate
Parliament House
Canberra ACT 2600

Phone: 02 6277 3515

Fax: 02 6277 5829

E-mail: community.affairs.sen@aph.gov.au

Internet: http://www.aph.gov.au/senate_ca

This document was produced by the Senate Community Affairs Committee Secretariat and printed by the Senate Printing Unit, Parliament House, Canberra.

MEMBERSHIP OF THE COMMITTEE

From 11 September 2006 ¹

Members

Senator Gary Humphries, Chairman	LP, Australian Capital Territory
Senator Claire Moore, Deputy Chair	ALP, Queensland
Senator Judith Adams	LP, Western Australia
Senator Lyn Allison	AD, Victoria
Senator Carol Brown	ALP, Tasmania
Senator Concetta Fierravanti-Wells	LP, New South Wales
Senator the Hon Kay Patterson	LP, Victoria
Senator Helen Polley	ALP, Tasmania

Participating Members

Senator Jeannie Ferris	LP, South Australia
Senator Ruth Webber	ALP, Western Australia

Senate Community Affairs References Committee

Until 10 September 2006

Members

Senator Claire Moore, Chair	ALP, Queensland
Senator Gary Humphries, Deputy Chairman	LP, Australian Capital Territory
Senator Judith Adams	LP, Western Australia
Senator Lyn Allison	AD, Victoria
Senator Carol Brown	ALP, Tasmania
Senator Helen Polley	ALP, Tasmania

Participating Members

Senator Jeannie Ferris	LP, South Australia
Senator Ruth Webber	ALP, Western Australia

¹ The Senate Committee system was restructured on 11 September 2006 to amalgamate the former legislation and references committees. The membership of committees was varied as part of the restructure. Inquiries that were current on 11 September continued with the same terms of reference and reporting dates.

TABLE OF CONTENTS

MEMBERSHIP OF THE COMMITTEE	<i>v</i>
LIST OF ACRONYMS	<i>xv</i>
EXECUTIVE SUMMARY	<i>xvii</i>
RECOMMENDATIONS	<i>ixx</i>
 CHAPTER 1	
INTRODUCTION	1
Terms of Reference	1
Conduct of the Inquiry.....	1
The Committee's report	2
Background to the Inquiry.....	2
What are gynaecological cancers?.....	3
The types of gynaecological cancers.....	4
Risk factors for gynaecological cancers.....	4
Prevention of gynaecological cancers	4
The symptoms of gynaecological cancers.....	5
Statistics on gynaecological cancers in Australia.....	6
Incidence of gynaecological cancers.....	6
Projections for new cases of gynaecological cancers.....	7
Deaths from gynaecological cancers.....	8
Survival rates for women with gynaecological cancers	9
Conclusion.....	10
 CHAPTER 2	
A STRONGER VOICE FOR GYNAECOLOGICAL CANCERS IN AUSTRALIA	11
Introduction	11
A national approach.....	12
The need for national coordination	12
A self-determining national body for gynaecological cancers.....	14
Benefits of a NGCC.....	14
Support from the Australian Society of Gynaecologic Oncologists.....	16
Support from community organisations	16
Relationship with Cancer Australia.....	17
Proposal for a National Women's Cancer Centre	17
A NGCC to be modelled on the NBCC.....	17
Location of a NGCC	19

Cost of NGCC.....	19
Improve existing arrangements.....	20
Expansion of the NBCC's remit to include gynaecological cancers	20
The need for a separate identity for gynaecological cancers.....	21
The way forward.....	21
CHAPTER 3	
ADEQUACY OF RESEARCH FUNDING FOR GYNAECOLOGICAL CANCERS.....	25
Introduction	25
Gynaecological cancer research	25
Clinical trials	25
The role of Australia New Zealand Gynaecological Oncology Group	26
Where is the research money coming from?	26
Commonwealth funding for gynaecological cancer research	26
Other Commonwealth research funding.....	27
The priority of research funding	28
Research and the National Breast Cancer Centre's Ovarian Cancer Program.....	28
Community funding for gynaecological cancer research.....	29
Cancer Councils' funding of gynaecological cancer research	31
Pharmaceutical company funding for gynaecological cancer research	32
International funding for gynaecological cancer research	32
Australian Ovarian Cancer Study	33
Incentives for research contributions	34
Adequacy of research funding for gynaecological cancers.....	34
Barriers to adequate gynaecological cancer research funding	36
Duplication and an uncoordinated approach.....	36
Lack of academic research positions.....	37
Lack of clinical trial funding.....	38
The importance of clinical trials	38
Australia's experience with gynaecological cancer clinical trials	38
Participation in clinical trials by Indigenous Australians and people living in rural, remote and regional communities.....	39
Adequacy of funding for clinical trials.....	40
Adequacy of NHMRC funding for clinical trials	41
Link between research funding and intellectual interest.....	42
Recommended funding levels for gynaecological cancer research.....	43
Future gynaecological cancer research needs.....	45
The priority of research	45
A commitment to ongoing funding	46

The continued need for collaboration.....	47
The need for a national approach	47
A screening test for ovarian cancer	48
Understanding the symptoms and causes of gynaecological cancers	50
Conclusion	51

CHAPTER 4

THE ADEQUACY OF GYNAECOLOGICAL CANCER CARE	53
Introduction	53
Gynaecological cancer services.....	53
Screening programs	54
Cervical cancer	55
What is a Pap test?	55
Liquid-based cytology	55
Adequacy of the existing Pap test for cervical cancer screening	56
Indigenous Australians and the Pap test	58
Utilising regional and rural nurses to conduct Pap tests.....	60
Human papilloma virus (HPV).....	60
HPV and cervical cancer.....	60
The difference between HPV DNA testing and the Pap test	61
The benefits of HPV DNA testing to cervical cancer screening	62
International advancements and HPV DNA testing	63
Australia's experience with HPV DNA testing.....	63
Potential benefits of HPV DNA testing for Australian women.....	64
HPV vaccines.....	65
Benefit of vaccines in Indigenous communities.....	66
The ability to screen for ovarian cancer	66
Treatment services.....	67
Multidisciplinary treatment	68
Adequacy of care and provision of treatment services.....	69
Issues that impact on the adequacy of treatment services	71
State and Commonwealth funding for treatment.....	71
Service provision in the private and public health systems.....	71
Lack of funding for database management infrastructure and resources	72
Staff shortages and lack of funding	74
Extended surgical waiting times	76
Inability to access Magnetic Resonance Imaging (MRI)	76
Adequacy of psychosocial treatment and services	77
Inadequacy of treatment provision to rural and remote areas	80
Tele-medicine and satellite clinics.....	81

Psychosocial service provision to rural and remote areas	81
The role of regional nurses and specialist nurses	82
Adequacy of treatment provision to Indigenous Australians	83
Adequacy of treatment for women from multicultural and linguistically diverse populations	85
The adequacy of interpreting services	85
Cultural differences impacting on treatment services	86
The adequacy of treatment to disadvantaged groups in Australia	87
Patient assisted travel schemes	87
Current arrangements	88
Accessing patient assistance	91
Other treatment and health support programs	94
Alternative and Complementary	94
Menopause	95
Lymphoedema	95
Support groups	98
Support for women during and after treatment	98
Conclusion	99

CHAPTER 5

GYNAECOLOGICAL CANCERS EDUCATION FOR THE MEDICAL COMMUNITY	103
Introduction	103
The importance of education	104
The medical community	104
General practitioners	105
Role	105
Current education strategies	106
Is the current level of education appropriate?	107
The way forward	109
Nurses	111
Role	111
Current education about gynaecological cancers	111
Is the current level of education appropriate?	112
The way forward	114
Allied health professionals	115
Gynaecologists	116
Gynaecological oncologists	116
General issues	117
Coordination and communication	117

Workforce shortages.....	118
Clinical practice guidelines	118
Education on emerging issues	119
Communication skills.....	119
Skills enhancement training	120
The Internet	120
Roles and responsibilities.....	121
Conclusion.....	121

CHAPTER 6

GYNAECOLOGICAL CANCERS EDUCATION FOR WOMEN AND THE COMMUNITY

Introduction	125
The importance of education.....	125
Awareness leads to empowerment	126
Improving awareness of the sub-specialty of gynaecological oncology.....	127
Eliminating the stigma associated with gynaecological cancers.....	127
Women and the broader community	127
Women	127
Broader community	128
Current education strategies	129
Current activities	129
Commonwealth Department of Health and Ageing	129
National Breast Cancer Centre's Ovarian Cancer Program	129
Cancer Councils.....	130
Community Organisations	130
Success of current activities	131
Vagueness of symptoms	132
Disproportionate focus on other cancers	132
Fragmented approach.....	133
Personal experiences needed	133
Misunderstanding about what Pap smears screen for (ie, only cervical cancer).....	134
Lack of media profile.....	134
Strategies for change	134
Areas of focus.....	135
Too much education?	135
A new, coordinated approach.....	136
National Awareness Campaign.....	136
Broader education about cancer.....	140

Factors to consider.....	140
One size does not fit all.....	140
Overcome stigma and use terminology correctly	141
Written information	141
Online information and e-medicine	142
Face-to-face contact important.	142
Consideration of population differences.....	143
Roles and responsibilities.....	143
Conclusion.....	144

CHAPTER 7

EXPERIENCE, EXPERTISE AND REPRESENTATION OF GYNAECOLOGICAL CANCER ISSUES

.....	147
Introduction	147
Experience and expertise in gynaecological cancers	147
Medical community and allied health community	147
Gynaecological cancer organisations	148
Professional bodies	148
Community organisations.....	149
The Cancer Councils.....	149
National health agencies, bodies and initiatives.....	150
Commonwealth Department of Health and Ageing.....	150
Cancer Australia	151
Issues regarding the operation of Cancer Australia.....	152
National Breast Cancer Centre	156
Roles and responsibilities in advising the Commonwealth Government.....	157
Policy advisory structures	157
Australian Health Ministers' Conference and Australian Health Ministers' Advisory Council.....	158
National Cancer Strategies Group and National Health Priority Action Council.....	158
The Australian Screening Advisory Committee.....	159
National Cancer Control Initiative.....	159
Representation of gynaecological oncology issues	160
The need for greater representation.....	160
Improved coordination and leadership	161
Conclusion.....	162

APPENDIX 1

LIST OF PUBLIC SUBMISSIONS AND TABLED DOCUMENTS
AUTHORISED FOR PUBLICATION BY THE COMMITTEE 165

APPENDIX 2

WITNESSES WHO APPEARED BEFORE THE COMMITTEE AT
PUBLIC HEARINGS 173

APPENDIX 3

NHMRC FUNDING FOR GYNAECOLOGICAL CANCER IN
AUSTRALIA 2000 – 2006 181

APPENDIX 4

POSSIBLE SEXUALITY ISSUES INVOLVED WITH GYNAECOLOGICAL
CANCER SURGERY 193

